Regulus Therapeutics (RGLS)
(Real Time Quote from BATS)
$2.22 USD
-0.07 (-3.06%)
Updated Jun 3, 2024 02:20 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 181 - 200 ( 270 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
July and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Alport Syndrome Program Enters the Clinic with Initiation of First-In-Human Study for RG-012; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals - June and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q1 Financials: Cash Runway Through Important Clinical Catalysts; Reiterate OUTPERFORM and $41 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
May and 2015 Emerging Pharmaceuticals Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
May and 2015 Emerging Pharmaceuticals Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Additional Analysis of Single Dose RG- 101 HCV Treatment Shows Durability: Material Phase 2 Results Likely in Q4; Reiterate OUTPERFORM and $41 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
EASL 50th International Liver Congress Preview for RG-101 in HCV; Reiterate OUTPERFORM and $41 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RG-125 (AZD4076) for T2D with NASH Is The Third Clinical Candidate Under Clinical Map Initiative 2015 Goal; Reiterate OUTPERFORM and $41 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RG-125 (AZD4076) for T2D with NASH Is The Third Clinical Candidate Under Clinical Map Initiative 2015 Goal; Reiterate OUTPERFORM and $41 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RG-125 (AZD4076) for T2D with NASH Is The Third Clinical Candidate Under Clinical Map Initiative 2015 Goal; Reiterate OUTPERFORM and $41 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
April and 2015 Emerging Pharmaceuticals Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RG-012 for Alport Syndrome Receives Orphan Drug Designation from EMA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RG-012 for Alport Syndrome Receives Orphan Drug Designation from EMA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
March and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
March and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q4/2014 Financials: We Project Cash Runway Through 2016 Next: RG-101 Phase 2 Design; Reiterate OUTPERFORM, Increase PT to $41 for Time Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Discontinuation of Coverage of the Biotech Sector
Provider: Brinson Patrick Securities Corporation